Prescient Therapeutics AGM 2024
Featured Speakers
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.
Previously, Steven had a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments. In particular, Steven leveraged his combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors.
Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has been a collaborator on various immunotherapy research projects.
Steven Engle
Non-Executive Chairman
Steven Engle has over two decades of experience leading biotechnology companies to develop and launch breakthrough therapies like the nicotine patch and has worked with the FDA in multiple disease areas, including cancer, diabetes, cardiovascular, and autoimmune. Most recently, Steve was the CEO of Gradalis, a privately-held biopharmaceutical company focused on the development of personalized cellular immunotherapies to treat cancer, and which is preparing a clinical study for product registration in patients with ovarian cancer. Prior to that, he was the CEO of CohBar, a clinical-stage, publicly-held biotechnology company developing mitochondria-based therapeutics to treat chronic diseases and extend healthy lifespan. Previously, he served as Chairman and CEO of antibody therapeutics company XOMA, which developed antibody drug candidates for many of the major pharmaceutical companies, and of B-cell tolerance therapeutics company, La Jolla Pharmaceutical Company, which focused on patients with Lupus. He is a former Director on the board of BIO and BayBio industry associations, and former Chair and Director of BIOCOM. Currently, Mr. Engle is a member of the board of directors of several companies. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with a focus in biomedical engineering.
